Advertisement

Product › Details
PEM technology (Protein Epitope Mimetic drug discovery technology)
![]() |
Next higher product group | drug discovery technology_oo |
![]() |
Status | 2015-12-01 production/use existent |
![]() |
Organisation | Polyphor Ltd. (SIX: POLN) |
Today | Spexis AG (SIX: SPEX) | |
Group | Spexis (Group) | |
Record changed: 2023-07-10 |
Advertisement

More documents for drug discovery technology_oo
- [1] Nuclera Ltd.. (10/16/24). "Press Release: Nuclera Closes $75 Million USD Financing > Series C round led by Elevage Medical Technologies". Cambridge & Boston, MA....
- [2] Quantro Therapeutics GmbH. (6/4/24). "Press Release: Quantro Therapeutics Reaches a Milestone in the Collaboration with Boehringer Ingelheim to Develop First-in-Class Cancer Treatments". Vienna....
- [3] LabGenius. (5/21/24). "Press Release: LabGenius Raises £35 Million Led by M Ventures to Further Develop Its ML-driven Antibody Discovery Platform and Progress a Pipeline of Assets Towards the Clinic". London....
- [4] Memo Therapeutics AG. (5/7/24). "Press Release: Memo Therapeutics Increases Series C Financing to CHF 45 Million". Schlieren....
- [5] PeptiDream Inc.. (4/30/24). "Press Release: PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis". Kanagawa....
- [6] Neurolentech GmbH. (4/22/24). "Press Release: Neurolentech Signs Technology Access Partnership with Kaerus Bioscience to Advance Neurodevelopmental Disorder Research". Klosterneuburg....
- [7] BioCopy AG. (4/9/24). "Press Release: BioCopy Expands Corporate Portfolio with Acquisition of Perspix Biotech GmbH". Basel....
- [8] AC Immune S.A.. (12/15/23). "Press Release: AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO". Lausanne....
- [9] Roche. (12/4/23). "Press Release: Roche Enters into a Definitive Merger Agreement to Acquire Carmot Therapeutics, including Three Clinical Stage Assets with Best-in-class Potential in Obesity and Diabetes". Basel....
- [10] Pieris Pharmaceuticals, Inc.. (8/17/23). "Press Release: Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific". Boston, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top